Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.07Wockhardt Ltd, a company in the Healthcare Services industry, showcases a mixed financial performance. The company demonstrates strong solvency, driven by healthy debt and equity management. Growth prospects are promising, particularly in revenue and operating profit. However, certain areas raise concern. The company's liquidity position appears weak, suggesting potential challenges in meeting short-term obligations. Efficiency in utilizing assets is also a concern. Profitability metrics are inconsistent, with strong gross and operating margins offset by low returns on equity and assets. Overall, Wockhardt shows potential for growth and stability, but needs to address its liquidity and efficiency challenges to achieve sustained financial health.
Health Score : 5.07Wockhardt Ltd, a company in the Healthcare Services industry, showcases a mixed financial performance. The company demonstrates strong solvency, driven by healthy debt and equity management. Growth prospects are promising, particularly in revenue and operating profit. However, certain areas raise concern. The company's liquidity position appears weak, suggesting potential challenges in meeting short-term obligations. Efficiency in utilizing assets is also a concern. Profitability metrics are inconsistent, with strong gross and operating margins offset by low returns on equity and assets. Overall, Wockhardt shows potential for growth and stability, but needs to address its liquidity and efficiency challenges to achieve sustained financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
94.85
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
141.16
P/B RATIO
6.09
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
7.81
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
40.90
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1850.6 as on Sep 1, 2026.
Growth Score : 6.00The company demonstrates strong growth in revenue and operating profit. The company has experienced decline in earnings per share, and net income growth rate is also low. However, the company has been able to grow its assets. The company's growth prospects appear to be promising, particularly in revenue and operating profit. Overall, the company's growth ratio indicates a mixed performance.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 19.28 | -17.93 | 5.55 | 7.65 | 11.99 |
| Operating Profit Growth Rate | 573.02 | -66.11 | -9.9 | 331.87 | 65.9 |
| Earnings Per Share (EPS) Growth | -135.56 | -129.04 | 22.22 | 90.42 | 553.63 |
| Asset Growth Rate | 6.08 | -6.87 | -0.48 | 6.38 | 6.36 |
| Net Income Growth Rate | -140.49 | -122.58 | 23.99 | 87.92 | 449.12 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 81.16 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | Marksans Pharma Ltd | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 9 | Syngene International Ltd | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 10 | ERIS Lifesciences Ltd | 7.15 | 29.07 | Neutral | 1120.00 | 17.61 | 648.00 |
| 11 | Piramal Pharma Ltd | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 12 | Jubilant Pharmova Ltd | 5.71 | 36.27 | Neutral | 1260.00 | 1.25 | 398.00 |
| 13 | Natco Pharma Ltd | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 14 | Strides Pharma Science Ltd | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 15 | Jeena Sikho Lifecare Ltd | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 16 | Wockhardt Ltd | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 17 | Pfizer Ltd | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
| 18 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 19 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤11th Jun 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Wockhardt Ltd. is a global pharmaceutical and biotechnology organization, focusing on the development, manufacturing, and marketing of pharmaceutical and biopharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines. It has a significant presence in India, the US, and the UK, with a strong emphasis on anti-infectives and chronic disease therapies.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Wockhardt Ltd's P/E ratio (TTM) is 94.85, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Wockhardt Ltd's P/B ratio is 6.09, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Wockhardt Ltd's P/S ratio is 7.81, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Wockhardt Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Wockhardt Ltd's EV/EBITDA ratio is 40.90.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Wockhardt Ltd's ROE is 4.03%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Wockhardt Ltd's ROA is 7.57%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Wockhardt Ltd's ROCE is 8%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Wockhardt Ltd's operating margin is 19.33%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Wockhardt Ltd's net margin is 5.90%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Wockhardt Ltd's current ratio is 1.48.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Wockhardt Ltd's debt-to-equity ratio is 0.33.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Wockhardt Ltd's interest coverage ratio is 2.12.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Wockhardt Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Wockhardt Ltd's EPS is 553.63.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹1850.60. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1967 (as Wockhardt Private Limited)
Headquarters: Mumbai, Maharashtra
Core Offerings: Pharmaceutical Formulations, Biopharmaceuticals, Active Pharmaceutical Ingredients (APIs), Vaccines, Specialty Pharmaceuticals
Stock Listing: NSE (WOCKPHARMA), BSE (532300)
Promoter: Khorakiwala Family / Dr. Habil Khorakiwala
Founded in 1967 by Dr. Habil Khorakiwala as Wockhardt Private Limited. The company went public in 1992, rapidly expanding its R&D and global footprint. Over the decades, it diversified into biopharmaceuticals and vaccines, establishing a global presence across key markets like the US and UK. Wockhardt has navigated regulatory challenges and financial restructuring, including a significant rights issue in 2020, while continuing its focus on anti-infectives and chronic therapies.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| India Business | 36% | Operating Profit |
| USA Business | 28% | Operating Profit |
| UK & Ireland Business | 15% | Operating Profit |
| Emerging Markets | 21% | Operating Profit |
India: Focuses on chronic and acute therapies across various segments like anti-infectives, pain management, diabetes, and CNS, leveraging a robust distribution network.
USA: Primarily deals in generic formulations, including niche products and complex injectables, through its subsidiary Wockhardt USA LLC.
UK & Ireland: Strong market presence in generics and branded generics, supported by manufacturing facilities such as CP Pharmaceuticals in Wrexham, UK.
Emerging Markets: Expanding operations in regions like Asia, Africa, CIS, and Latin America with a diverse product portfolio catering to local healthcare needs.
Dr. Habil Khorakiwala - Founder Chairman. A visionary leader, he founded Wockhardt and has been instrumental in shaping its journey into a global pharmaceutical enterprise. Dr. Murtaza Khorakiwala - Managing Director. He holds an MBA from the University of Illinois and guides the company's strategic direction and global operations. Dr. Huzaifa Khorakiwala - Joint Managing Director. With an MBA from Yale University, he oversees various corporate functions and new strategic initiatives.
Wockhardt UK Limited (UK)
CP Pharmaceuticals Limited (UK)
Wockhardt USA LLC (USA)
Wockhardt Bio AG (Switzerland)
Wockhardt EU Operations (Ireland)
Rights Issue of ₹748 crore in 2020. Divestment of certain identified businesses (including its India business for a portfolio of 62 brands and manufacturing facilities) to Dr. Reddy's Laboratories in 2020.
The Wockhardt Ltd share price today is ₹1850.60 on NSE (WOCKPHARMA), as of 26 Sept 2026.
As of 25 Sept 2026, Wockhardt Ltd share price is ₹1850.60, with previous close ₹1850.60. Today's range is ₹1850.60 to ₹1850.60. The 52-week range is ₹1086.70 to ₹2422.30.
As of today, Wockhardt Ltd's market cap is ₹26,352.54 crore (Large Cap).
Wockhardt Ltd's current P/E ratio is 94.85, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of N/A.
Wockhardt Ltd's current P/B ratio is 6.09.
Wockhardt Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Wockhardt Ltd's EPS (TTM) is ₹553.63.
Wockhardt Ltd. is a global pharmaceutical and biotechnology organization, focusing on the development, manufacturing, and marketing of pharmaceutical and biopharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines. It has a significant presence in India, the US, and the UK, with a strong emphasis on anti-infectives and chronic disease therapies.
Wockhardt Ltd is promoted by Khorakiwala Family / Dr. Habil Khorakiwala, holding 49.08% as of 25 Sept 2026.
Wockhardt Ltd is listed on NSE (WOCKPHARMA) and BSE (532300). Its next quarterly results are expected on Q1 FY25 (Expected Late July / Early August 2024).
